IndustryCompany release
Cypherpunk reports $306M Q3 net income as Leap starts sirexatamab partnering process
🇺🇸 Cypherpunk Technologies Inc. (CYPH) · Mon 16 Nov 2026
The Nasdaq-listed Zcash treasury company says a non-cash derivative gain drove its profit, while its Leap Therapeutics unit seeks funding or a partner for a colorectal cancer candidate.
Cypherpunk Technologies, formerly known as Leap Therapeutics, reported third-quarter 2026 results on 16 November 2026. The Nasdaq-listed company holds a Zcash treasury and retains Leap Therapeutics as a subsidiary.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Cypherpunk Technologies Inc. ↗
Article written by VigiEye from the official source (Cypherpunk Technologies Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative
🇺🇸 Microbot Medical Inc. (MBOT) · Mon 16 Nov 2026
TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales
TOYO Co., Ltd (TOYO) · Mon 16 Nov 2026
Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers
EoCene Ltd. (EOCN) · Mon 16 Nov 2026
Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC
🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Mon 16 Nov 2026
Adagio Medical's VT ablation PMA remains under FDA review as board explores strategic alternatives
🇺🇸 Adagio Medical Holdings, Inc. (ADGM) · Mon 16 Nov 2026